Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia

Hydroxyurea therapy has proven laboratory and clinical efficacies for children with sickle cell anemia (SCA). When administered at maximum tolerated dose (MTD), hydroxyurea increases fetal hemoglobin (HbF) to levels ranging from 10% to 40%. However, interpatient variability of percentage of HbF (%Hb...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Ware, Russell E., Despotovic, Jenny M., Mortier, Nicole A., Flanagan, Jonathan M., He, Jin, Smeltzer, Matthew P., Kimble, Amy C., Aygun, Banu, Wu, Song, Howard, Thad, Sparreboom, Alex
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society of Hematology 2011
נושאים:
Clinical Trials and Observations
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3208303/
https://ncbi.nlm.nih.gov/pubmed/21876119
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-07-364190
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים